- United States
- Healthcare Services
Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues
Celebrations may be in order for 23andMe Holding Co. (NASDAQ:ME) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The revenue forecast for next year has experienced a facelift, with analysts now much more optimistic on its sales pipeline.
After this upgrade, 23andMe Holding's dual analysts are now forecasting revenues of US$345m in 2023. This would be a huge 33% improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$313m in 2023. It looks like there's been a clear increase in optimism around 23andMe Holding, given the decent improvement in revenue forecasts.
See our latest analysis for 23andMe Holding
The consensus price target fell 26% to US$8.50, with the analysts clearly less optimistic about 23andMe Holding's valuation following this update. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic 23andMe Holding analyst has a price target of US$11.00 per share, while the most pessimistic values it at US$6.00. This shows there is still some diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. One thing stands out from these estimates, which is that 23andMe Holding is forecast to grow faster in the future than it has in the past, with revenues expected to display 25% annualised growth until the end of 2023. If achieved, this would be a much better result than the 22% annual decline over the past three years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 8.2% annually. So it looks like 23andMe Holding is expected to grow faster than its competitors, at least for a while.
The Bottom Line
The highlight for us was that analysts increased their revenue forecasts for 23andMe Holding next year. They're also forecasting more rapid revenue growth than the wider market. The consensus price target fell measurably, with analysts seemingly not reassured by recent business developments, leading to a lower estimate of 23andMe Holding's future valuation. Seeing the dramatic upgrade to next year's forecasts, it might be time to take another look at 23andMe Holding.
Looking for more information? We have analyst estimates for 23andMe Holding going out to 2024, and you can see them free on our platform here.
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.
Valuation is complex, but we're helping make it simple.
Find out whether 23andMe Holding is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
23andMe Holding Co. operates as a consumer genetics testing company.
Flawless balance sheet with weak fundamentals.